Since the aim of this study, by identifying a new possible molecular target, is to provide the possibility of administering new combined therapies in tumors with an activated MAPK pathway, it could be interesting to include among future objectives the study of a possible synergistic effect between the drugs targeting tumor metabolism and inhibitors of the MAPK pathway targeting p90RSK. Here, RPS6KA1 is linked to neoplasm.